• Click-Compatible BmTyr in Primary T Cells

  2026-10-09

  The 2026 study introduces an engineered BmTyr tyrosinase platform for biotin-free, click-compatible proximity labeling in primary T cells. By combining alkyne-phenol labeling with azide-bearing imaging, enrichment, and validation tags, the authors mapped local proteomes and identified chromatin-associated localization of NKAP.

• Lopinavir in MERS-CoV Repurposing Research

  2026-10-09

  The study by de Wilde and colleagues screened 348 FDA-approved compounds and identified Lopinavir, chloroquine, chlorpromazine, and loperamide as low-micromolar inhibitors of MERS-CoV replication in cell culture. Its main contribution was a rapid repurposing framework with activity extending to SARS-CoV and human coronavirus 229E, while the findings remained preclinical and did not establish mechanism, animal efficacy, or clinical benefit.

• HFPO-DA, CK2, and Ischemic Stroke Neuroinflammation

  2026-10-08

  A 2026 study reports that HFPO-DA worsened ischemic brain injury in rats and identifies the CSNK2A1/GSK3B/NF-κB axis as a mechanistic candidate. Its integrated animal, cellular, computational, and pharmacological evidence connects an environmental contaminant with microglia-associated neuroinflammation, while leaving important questions about human exposure relevance and pathway specificity.

• EMD638683: SGK1 Evidence in Vascular Research

  2026-10-08

  EMD638683 is a small-molecule SGK-family inhibitor used as a research tool to examine SGK1 signaling. The strongest supplied evidence comes from a 2024 study linking endothelial SGK1 to salt- and mineralocorticoid-associated vascular stiffening; claims involving cancer, blood pressure, and broader kinase selectivity remain more dependent on supplier-reported data or require independent replication.

• Dasatinib Monohydrate in Gastric Cancer Models

  2026-10-07

  Dasatinib Monohydrate, also known as BMS-354825, has an established research and clinical context in ABL- and SRC-driven hematologic malignancies. A 2025 patient-derived gastric cancer assembloid study shows why stromal context can change drug responses, but it does not establish dasatinib efficacy in gastric cancer. This overview separates reported findings from hypothesis-generating applications and explains the model’s limitations.

• CGRP/SP–Piezo2 Signaling in Trigeminal Neuralgia

  2026-10-07

  Liao et al. identify a Ca2+-dependent CGRP/SP–Piezo2 positive-feedback loop linking trigeminal root compression, neuroinflammation, and mechanical allodynia in a rat model of trigeminal neuralgia. The study provides a mechanistic framework for understanding how TG neurons and peripheral Merkel cells may cooperate to amplify touch-evoked pain, while remaining limited by its preclinical design and tissue-specific evidence.

• Annexin V and the Translational Logic of Cell Death

  2026-10-06

  Phosphatidylserine externalization offers a mechanistically informative view of cell death before DNA fragmentation becomes prominent. This thought-leadership article examines how Annexin V, a phosphatidylserine binding protein, was validated in a murine ischemia–reperfusion model, where labeled recombinant human Annexin V tracked increasing cardiomyocyte death and responded to a cell-death intervention. It also defines the evidence boundaries, compares Annexin V with complementary readouts, and outlines how translational researchers can use PS biology to build more coherent apoptosis and cell death research strategies.

• HDAC Inhibitors Repress NUT Carcinoma Programs

  2026-10-06

  Shiota et al. developed a dCas9-based transcriptional reporter screen that identified structurally diverse HDAC inhibitors as suppressors of NUT-driven transcription. The study connects HDAC inhibition with loss of BRD4-NUT megadomains, reduced oncogenic gene expression, differentiation, and tumor-growth control, while also defining important limits for therapeutic interpretation.

• YM 58483 (BTP2): SOCE Research Context

  2026-10-05

  YM 58483, also called BTP2, is a pharmacological probe used to investigate store-operated calcium entry, immune-cell activation, and emerging fibrosis mechanisms. This overview compares supplier-reported activity with findings from a 2025 salivary-gland study, emphasizing what the evidence supports, where interpretation remains uncertain, and why BTP2 should not be treated as an ORAI2-specific or clinically validated therapy.

• Anlotinib and VEGFR2: Preclinical Evidence

  2026-10-05

  The reference study established anlotinib as a highly potent and selective VEGFR2 inhibitor with anti-angiogenic activity across biochemical, cellular, ex vivo, and animal models. Its findings support a vascular mechanism of tumor control, while also showing why strong preclinical activity should not be equated with direct tumor-cell cytotoxicity or clinical efficacy.

• Anlotinib in Desmoplastic Small Round Cell Tumors

  2026-10-04

  This case report and literature review describes radiographic regression of metastatic intra-abdominal desmoplastic small round cell tumor during anlotinib treatment after surgery and chemotherapy. The finding is hypothesis-generating rather than confirmatory, but it identifies a clinically relevant rationale for studying multi-target tyrosine kinase inhibition in a rare tumor with few standardized treatment options.

• Live-Dead Cell Staining Kit Overview

  2026-10-03

  The APExBIO Live-Dead Cell Staining Kit (SKU K2081) is described as a two-dye fluorescence product for distinguishing membrane-intact and membrane-compromised cells in cultured populations. No matched paper evidence was provided, so its performance, reproducibility, and suitability across models or instruments cannot be independently assessed here.

• HAUS1 in HCC: Immune Microenvironment and Proliferation

  2026-10-02

  The reference study integrates public transcriptomic, clinical, protein-expression, immune-infiltration, and siRNA data to define HAUS1 as a potential biomarker and functional driver in hepatocellular carcinoma. Its results connect elevated HAUS1 with adverse prognosis, tumor-cell proliferation, invasion, cell-cycle regulation, apoptosis, and immune-checkpoint context, while also highlighting the need for prospective and mechanistic validation.

• Bromodomain Inhibitor, (+)-JQ1 in Ferroptosis Assays

  2026-10-01

  Bromodomain Inhibitor, (+)-JQ1 provides a mechanistically focused way to study how BRD4 inhibition reshapes ferroptosis sensitivity. This guide translates recent ROS and FSP1 findings into assay design, interpretation, and cross-domain research decisions.

• Maraviroc (UK-427857): CCR5 Assay Workflows

  2026-10-01

  Build reproducible CCR5 experiments with Maraviroc, from HIV-1 entry inhibition and HIV tropism studies to extracellular-vesicle inflammation models. This practical guide combines product handling, assay controls, reference-driven EV workflows, and troubleshooting without overstating preclinical evidence.

8046 records 1/537 page Next 12345 下5页 Last page